Marck Biosciences, manufacturer and marketer of sterile liquids pharmaceutical dosages using the Blow-Fill-Seal (BFS) technology, has sold a minority stake to Tata Capital Healthcare Fund. Tata Capital will invest Rs 45 crores in the company and has picked up a 13 per cent stake in Marck Biosciences. IFCI Venture’s six per cent stake will also be acquired by Tata Capital Healthcare Fund. Hence, Tata Capital will hold around 19 per cent to 22 per cent combined stake in Marck Biosciences.
Marck Biosciences is targeting a top line growth of 62 per cent while the PBDIT (Profit before interest, depreciation & taxes) is targeted at 37 per cent and net profit to reach at 17-18 per cent.
Speaking on this occasion, Bhavesh Patel, Managing Director, Marck Biosciences said, “It is a sustained growth phase for us at Marck Biosciences as we are investing Rs 80 crores in the new expansion project. The fund infusion from Tata Capital will be invested for further expansion of capacities of the new project which will have state of the art technology. Our entire project cost is expected to be around Rs 80 crores and hence we will also be going in for further funding through debt route. We expect returns from the funds infused within six to eight months.”
Marck Biosciences is actively seeking opportunities for growth and expansion in both markets, domestic and international. Hence the expansion of production facilities, product portfolio and markets becomes vital.
EP News Bureau